Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women

Medical Care

Volumn 38, Issue 9, 2000, Pages 911-925

  Turner, Barbara J ^a   Newschaffer, Craig J ^b   Zhang, Daozhi ^c   Cosler, Leon ^d   Hauck, Walter W ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

Ambulatory care; Anti HIV agents; Patient com; Pliance; Substance related disorders; Women

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AMBULATORY CARE; ARTICLE; DISEASE TRANSMISSION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAID; PATIENT COMPLIANCE; PREGNANCY; PREGNANCY COMPLICATION; PUERPERIUM; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

ADULT; AMBULATORY CARE; ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MEDICAID; NEW YORK; PATIENT COMPLIANCE; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; UNITED STATES;

EID: 0034268595     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-200009000-00005     Document Type: Article

References (54)

1. Centers for Disease Control and Prevention. Success in implementing Public Health Service guidelines to reduce perinatal transmission of HIV: Louisiana, Michigan, New Jersey, and South Carolina, 1993, 1995, and 1996. MMWR Morb Mortal Wkly Rep 1998;47:688-691.
2. Cooper ER, Nugent RP, Diaz C, Pitt J, Hanson C, Kalish LA, et al. After AIDS Clinical Trial 076: The changing pattern of zidovudine use during pregnancy and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants: Women and Infants Transmission Study Group. J Infect Dis 1996;174:1207-1211.
3. Fiscus SA, Adimora AA, Schoenbach VJ, Lim W, McKinney R, Rupar D, et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA 1996;275:1483-1488.
4. Turner BJ, Newschaffer CJ, Zhang D, Fanning TR, Hauck WW. Translating clinical trial results into practice: The effect of an AIDS clinical trial on prescribed antiretroviral therapy for HIV-infected, pregnant women. Ann Intern Med 1999;130:979-986.
5. Turner BJ, Markson LE, Mauskopf J, Houchens R, Fanning TR. Health care delivery, zidovudine use, and survival of women and men with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1994;7:1250-1262.
6. Strathdee SA, Palepu A, Cornelisse PG, Yip B, O'Shaughnessy MV, Montaner JS, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998;280:547-549.
7. Stone VE, Clarke J, Lovell J, Steger KA, Hirschhorn LR, Boswell S, et al. HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. J Gen Intern Med 1998;13:586-593.
8. Would use of specialists improve patient care? AIDS Alert 1998;13:87-89.
9. Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:117-125.
10. Johnston BE, Ahmad K, Smith C, Rose DN. Adherence to highly active antiretroviral therapy among HIV-infected patients of the inner city. Int Conf AIDS 1998;12:599. Abstract 32389.
11. Mannheimer S, Hirsch Y, el-Sadr W. The impact of the ALR alarm device on antiretroviral (AR) adherence among HIV-infected outpatients in Harlem. Int Conf AIDS 1998;12:585-586. Abstract 32325.
12. Arabe J, Rubini NP, Rodrigues AC, Leal DW, Freitas EH, Sion FS, et al. Factors which influence adherence to the use of protease inhibitors. Int Conf AIDS 1998;12:602-603. Abstract 32404.
13. Arnsten JH, Demas PA, Gourevitch MN, Buono D, Farzadegan H, Schoenbaum EE. Adherence to chemotherapeutic regimens. Presented at the Seventh Conference on Retroviruses and Opportunistic Infections; January 2000; San Francisco, Calif. Session 12, abstract 69.
14. Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance. AIDS Care 1996;8:261-269.
15. Ohmit S, Schuman P, Schoenbaum E, Rompalo A, Cohen M, Richardson J, et al. Adherence to antiretroviral therapy (ART) among women in the HIV Epidemiology Research Study (HERS) and Women's In ter-Agency HIV Study (WIHS). Int Conf AIDS 1998;12:590. Abstract 32347.
16. Nokes KM, Corless IB, Brown MA, Turner JG, Powell-Cope GM, Inouye J, et al. Are there gender differences in HIV adherence? Int Conf AIDS 1998;12:589. Abstract 32339.
17. Williams A, Wolf H, Yu C, Singh M. Adherence to antiretroviral therapy among HIV positive women. Int Conf AIDS 1998;12:596. Abstract 32374.
18. Lindegren ML, Wortley P. Trends in zidovudine prescription for pregnant women infected with HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:289-292.
19. Turner BJ, Hauck WW, Fanning TR, Markson LE. Cigarette smoking and maternal-child HIV transmission. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:327-337.
20. Sande MA, Carpenter CCJ, Cobbs CG, Holmes KK, Sanford JP. Antiretroviral therapy for adult HIV-infected patients: recommendations from a state-of-the-art conference. JAMA 1993;270:2583-2589.
21. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1996: Recommendations of an international panel. JAMA 1996;276:146-155.
22. Bozzette SA, Berry SH, Duan N, Frankel MR, Leibowitz AA, Lefkowitz D, et al. The care of HIV-infected adults in the United States: HIV Cost and Services Utilization Study Consortium. N Engl J Med 1998;339:1897-1904.
23. Maher K, Klimas N, Fletcher MA, Cohen V, Maggio CM, Triplett J, et al. Disease progression, adherence, and response to protease inhibitor therapy for HIV infection in an urban veterans affairs medical center. AIDS 1999;22:358-363.
24. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence of use of lipid-lowering medications: A cross-national study. JAMA 1998;279:1458-1462.
25. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-116.
26. Sclar DA, Chin A, Skaer TL, Okamoto MP, Nakahiro RK, Gill MA. Effect of health education in promoting prescription refill compliance among patients with hypertension. Clin Ther 1991;13:489-495.
27. Hecht FM, Colfax G, Swanson M, Chesney MA. Adherence and effectiveness of protease inhibitors in clinical practice. Presented at the Fifth Conference on Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, IL.
28. Altice FL, Mostashari F, Thompson AS, Friedland GH. Perceptions, acceptance and adherence to antiretrovirals among prisoners. Presented at the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington D.C. Abstract 253.
29. Designated care programs for patients with AIDS and HIV-related illnesses in designated care centers. N Y State J Med 1989;89:542-543.
30. Reimbursement rates for facilities participating in the HIV Primary Care Medicaid Program. Albany, NY: Department of Health; November 4, 1993. Health Facilities Series H-23, D&TC-17, HMO-16, 93-95.
31. Fanning TR, Turner BJ, Cosler LE, Oetjen-Gerdes L, Markson LE, McKee L, et al. Quality of Medicaid data for HIV/AIDS research: Examination of a statewide database. AIDS Public Pol J 1995;10:39-47.
32. Christensen DB, Williams B, Goldberg HI, Martin DP, Engelberg R, LoGerfo JP. Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med Care 1997;35:1164-1170.
33. Laine C, Newschaffer CJ, Zhang D, Cosler L, Hauck WW, Turner BJ. Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: A pharmacy claims-based analysis. Obstet Gynecol 2000;95:167-173.
34. Turner BJ, Markson LE, Taroni F. Estimation of survival after AIDS diagnosis: CD4 T-lymphocyte count versus clinical severity. J Clin Epidemiol 1996;49:59-65.
35. Turner BJ, Markson LE, McKee L, Houchens R, Fanning T. The AIDS-defining diagnosis and subsequent complications: A survival-based severity index. J Acquir Immune Defic Syndr Hum Retrovirol 1991;4:1059-1071.
36. Tseng AL. Compliance issues in treatment of HIV infection. Am J Health Syst Pharm 1998;55:1817-1824.
37. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-1586.
38. Spira R, Marimoutou C, Binquet C, Lacoste D, Dabis F. Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France, 1995-1997. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:358-364.
39. Morse EV, Simon PM, Coburn M, Hyslop N, Greenspan D, Balson PM. Determinants of subject compliance within an experimental anti-HIV drug protocol. Soc Sci Med 1991;32:1161-1167.
40. Smith SR, Kirking DM. Access and use of medications in HIV disease. Med Care 1999;34:123-144.
41. Kastrissios H, Suarez JR, Katzenstein D, Girard P, Sheiner LB, Blaschke TF. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS 1998;12:2295-2303.
42. Blackwell B. Drug therapy: patient compliance. N Engl J Med 1971:249-252.
43. Altice FL, Friedland GH. The era of adherence to HIV therapy. Ann Intern Med 1998;129:503-505.
44. Barthwell AG. Substance use and the puzzle of adherence. Focus 1997;12:1-4.
45. McChance-Katz EF, Rainey PM, Jatlow P, Friedland G. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:435-443.
46. Gourevitch MN. Methadone and antiretroviral medications, part I: AIDS Clinical Care 1999;11:30-31.
47. Stone VE, Mauch MY, Steger K, Janas SF, Craven DE. Race, gender, drug use, and participation in AIDS clinical trials: Lessons from a municipal hospital cohort. J Gen Intern Med 1997;12:150-157.
48. Hankins C, Lapointe N, Walmsley S. Participation in clinical trials among women living with HIV in Canada: Canadian Women's HIV Study Group. Can Med Assoc J 1998;159:1359-1365.
49. Paes AH, Bakker A, Soe-Agnie CJ. Measurement of patient compliance. Pharm World Sci 1998;20:73-77.
50. Woodward J, Wareham PS, Grohskopf L, Madigan D, Hooton TM. Protease inhibitor adherence and HIV-1 RNA response. Presented at the 12th World Conference on AIDS; June 28-July 3, 1998; Geneva, Switzerland. Abstract 60363.
51. Lin EH, Von Korff M, Katon W, Bush T, Simonn GE, Walter E, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995;33:67-74.
52. Squier RW. A model of empathetic understanding and adherence to treatment regimens in practitioner-patient relationships. Soc Sci Med 1990;30:325-339.
53. Mostashari F, Riley E, Selwyn PA, Altice FL. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:341-348.
54. Smith MY, Rapkin BD, Morrison A, Kammerman S. Zidovudine adherence in persons with AIDS: The relation of patient beliefs about medication to self-termination of therapy. J Gen Intern Med 1997;12:216-223.